Exchange Traded Concepts LLC boosted its stake in shares of Precigen, Inc. (NASDAQ:PGEN – Free Report) by 10.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 167,496 shares of the biotechnology company’s stock after acquiring an additional 15,525 shares during the period. Exchange Traded Concepts LLC’s holdings in Precigen were worth $159,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of PGEN. Fisher Asset Management LLC bought a new position in Precigen during the fourth quarter valued at $29,000. Fortis Group Advisors LLC purchased a new position in shares of Precigen during the 1st quarter worth about $28,000. Iridian Asset Management LLC CT boosted its stake in shares of Precigen by 4.3% during the 1st quarter. Iridian Asset Management LLC CT now owns 2,091,274 shares of the biotechnology company’s stock worth $3,032,000 after purchasing an additional 86,340 shares during the period. Vanguard Group Inc. boosted its stake in shares of Precigen by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after purchasing an additional 19,875 shares during the period. Finally, EntryPoint Capital LLC purchased a new position in shares of Precigen during the 1st quarter worth about $31,000. Institutional investors own 33.51% of the company’s stock.
Insider Transactions at Precigen
In other Precigen news, SVP Jeffrey Thomas Perez purchased 58,823 shares of the stock in a transaction dated Friday, August 9th. The stock was purchased at an average price of $0.85 per share, with a total value of $49,999.55. Following the transaction, the senior vice president now owns 743,097 shares of the company’s stock, valued at approximately $631,632.45. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 44.90% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Analysis on Precigen
Precigen Price Performance
Precigen stock opened at $0.93 on Tuesday. The firm has a 50-day moving average of $1.00 and a two-hundred day moving average of $1.31. Precigen, Inc. has a 1 year low of $0.82 and a 1 year high of $1.93. The stock has a market cap of $234.36 million, a price-to-earnings ratio of -1.72 and a beta of 1.66.
Precigen (NASDAQ:PGEN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Precigen had a negative return on equity of 90.99% and a negative net margin of 3,084.55%. The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $1.28 million. Research analysts expect that Precigen, Inc. will post -0.44 earnings per share for the current year.
Precigen Profile
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
See Also
- Five stocks we like better than Precigen
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What Are Some of the Best Large-Cap Stocks to Buy?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. (NASDAQ:PGEN – Free Report).
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.